Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

NCT00646503 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-06-22

No results posted yet for this study

Summary

This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Telbivudine

600 mg/day, oral telbivudine for 52 weeks

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646503 on ClinicalTrials.gov